Trexquant Investment’s Design Therapeutics DSGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$559K Buy
44,449
+16,299
+58% +$225K ﹤0.01% 1632
2026
Q2
$407K Sell
28,150
-88,961
-76% -$1.11M ﹤0.01% 1689
2026
Q1
$1.25M Buy
117,111
+17,144
+17% +$173K 0.01% 1155
2025
Q4
$938K Buy
+99,967
New +$783K 0.01% 1202
2023
Q3
– Sell
-46,524
Closed -$293K – 1540
2023
Q2
$293K Sell
46,524
-4,315
-8% -$26.4K 0.01% 1204
2023
Q1
$293K Buy
+50,839
New +$380K 0.01% 1212
2022
Q4
– Sell
-11,296
Closed -$189K – 1442
2022
Q3
$189K Buy
+11,296
New +$225K 0.01% 1204

Other funds holding DSGN

Trexquant Investment's DSGN Position: Q3 2026 in Review

Trexquant Investment increased its Design Therapeutics (DSGN) stake by 58% in Q3 2026, buying an estimated $225K and bringing the position to 44,449 shares worth $559K. The position accounts for ﹤0.01% of the portfolio, ranked #1632.

Trexquant Investment first reported a position in DSGN in Q3 2022 and has held it in 7 quarters since. The position peaked at $1.25M in Q1 2026. 142 funds tracked by Wall St. Rank hold DSGN as of Q3 2026.

  • Trexquant Investment held 44,449 shares of Design Therapeutics worth $559K as of Q3 2026.
  • Trexquant Investment bought 16,299 Design Therapeutics shares in Q3 2026, an estimated $225K.
  • Design Therapeutics made up ﹤0.01% of Trexquant Investment's portfolio in Q3 2026, its #1632 holding.
  • Trexquant Investment first reported a position in Design Therapeutics in Q3 2022 and has held it in 7 quarters since.
  • Trexquant Investment's Design Therapeutics position peaked at $1.25M in Q1 2026.
  • 142 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2026.

Based on Trexquant Investment's 13F filing for Q3 2026, filed 16 Nov 2026.